Eptacog alfa activated: A recombinant product to treat rare congenital bleeding disorders

Blood Reviews

Volumn 29, Issue S1, 2015, Pages S26-S33

  Minno, Giovanni Di ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Congenital factor VII deficiency; Glanzmann's thrombasthenia; Glanzmann's Thrombasthenia Registry (GTR); Recombinant activated factor VII; Seven Treatment Evaluation Registry (STER); Surgery

Indexed keywords

ANTIFIBRINOLYTIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL TRIAL (TOPIC); CONGENITAL FACTOR VII DEFICIENCY; DISEASE REGISTRY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; GLANZMANN DISEASE; HEMOSTASIS; HUMAN; OPERATIVE BLOOD LOSS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; TREATMENT FAILURE; ANIMAL; HEMOPHILIA A; THROMBASTHENIA;

ANIMALS; FACTOR VIIA; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS; THROMBASTHENIA;

EID: 84931375056     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/S0268-960X(15)30005-9     Document Type: Article

References (51)

1. Di Minno G, Coppola A, Di Minno MN, Poon MC Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009, 102:1157-1164.
2. Lapecorella M, Mariani G Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia 2008, 14:1170-1175.
3. Di Minno G, d'Oiron R, Zotz R, Poon M-C Treatment modalities and outcomes in 870 non-surgical bleeds in 184 Glanzmann's thrombasthenia patients: the International Prospective Glanzmann's Thrombasthenia Registry [Accessed April 8, 2015]. http://www.eventure-online.com/eventure/public/publicAbstractView.form?id=217038&congressId=6839.
4. Poon M-C, d'Oiron R, Zotz R, Di Minno G Treatment modalities and outcomes in 204 surgical procedures in 96 Glanzmann's thrombasthenia (GT) patients: the International Prospective Glanzmann's Thrombasthenia Registry (GTR). J Thromb Haemost 2013, 11(Suppl. 2):161.
5. Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006, 43(1 Suppl. 1):S33-S36.
6. Mariani G, Napolitano M, Dolce A, Perez Garrido R, Batorova A, Karimi M, et al. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation. Thromb Haemost 2013, 109:238-247.
7. Napolitano M, Giansily-Blaizot M, Dolce A, Schved JF, Auerswald G, Ingerslev J, et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 2013, 98:538-544.
8. ® summary of product characteristics [Accessed March 3, 2015]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000074/WC500030873.pdf.
9. ® RT Highlights of Prescribing Information [Accessed April 8, 2015]. http://www.fda.gov/downloads/.../ucm056954.pdf.
10. ® Product Monograph [Accessed April 8, 2015]. http://webprod5.hc-sc.gc.ca/dpd-bdpp/.
11. Bellucci S, Caen J Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment. Blood Rev 2002, 16:193-202.
12. Nurden AT, Pillois X, Wilcox DA Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost 2013, 39:642-655.
13. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol 2004, 77:198-199.
14. George JN, Caen JP, Nurden AT Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990, 75:1383-1395.
15. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006, 135:603-633.
16. Rajpurkar M, Chitlur M, Recht M, Cooper DL Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia 2014, 20:464-471.
17. Spiess BD Platelet transfusions: the science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol 2010, 24:65-83.
18. MacLennan S, Williamson LM Risks of fresh frozen plasma and platelets. J Trauma 2006, 60(6 Suppl.):S46-S50.
19. Hedner U Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008, 100:557-562.
20. Lisman T, Adelmeijer J, Heijnen HF, de Groot PG Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004, 103:1720-1727.
21. Poon MC, Demers C, Jobin F, Wu JW Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999, 94:3951-3953.
22. Poon MC, d'Oiron R, Von Depka M, Khair K, Négrier C, Karafoulidou A, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004, 2:1096-1103.
23. Study ID F7Haem-3521 F7GLANZ. Non-interventional study report: study abstract [Accessed March 30, 2015]. http://novonordisk-trials.com/Website/pdf/registry/bin_20141031-012557-143.pdf.
24. Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MND, Poon M-C The international prospective Glanzmann Thrombasthenia Registy: treatment modalities and outcomes in non-surgical bleeding episodes in Glanzmann thrombasthenia patients. Haematologica 2015;May 22, pii: haematol.2014.121475.
25. Poon M-C, d'Oiron R, Zotz RB, Bindslev N, Di Minno MND, Di Minno G The international prospective Glanzmann Throbasthenia Registry: treatment and outcomes in surgical intervention. Haematologica 2015;May 22, pii: haematol.2014.121384.
26. Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P Rare bleeding disorders. Haemophilia 2012, 18(Suppl. 4):148-153.
27. Perry DJ Factor VII Deficiency. Br J Haematol 2002, 118:689-700.
28. World Federation of Hemophilia. Report on the Annual Global Survey [Accessed March 3, 2015]. http://www1.wfh.org/publication/files/pdf-1427.pdf.
29. Borhany M, Pahore Z, Ul Qadr Z, Rehan M, Naz A, Khan A, et al. Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis 2010, 5:23.
30. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005, 93:481-487.
31. Di Minno MND, Batorova A, Napolitano M, Dolce A, Di Minno G, Bernardi F, et al. At disease presentation, severity of the bleeding symptoms predicts the following bleeds in patients with FVII deficiency. Blood 2011, 118:543.
32. Mariani G, Bernardi F Factor VII Deficiency. Semin Thromb Hemost 2009, 35:400-406.
33. Giansily-Blaizot M, Biron-Andreani C, Aguilar-Martinez P, de Moeloose P, Briquel ME, Goudemand J, et al. Inherited factor VII deficiency and surgery: clinical data are the best criteria to predict the risk of bleeding. Br J Haematol 2002, 117:172-175.
34. Mariani G, Dolce A, Napolitano M, Ingerslev J, Giansily-Blaizot M, Di Minno MD, et al. Invasive procedures and minor surgery in factor VII deficiency. Haemophilia 2012, 18:e63-e65.
35. Mariani G, Konkle BA, Ingerslev J Congenital factor VII deficiency: therapy with recombinant activated factor VII - a critical appraisal. Haemophilia 2006, 12:19-27.
36. Berrettini M, Mariani G, Schiavoni M, Rocino A, Di Paolantonio T, Longo G, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001, 86:640-645.
37. Greenberg DL, Davie EW Blood coagulation factors: Their complementary DNAs, genes and expression. Hemostasis and Thrombosis 2001, 135-156. Lippincott Williams & Wilkins, Philadelphia. R.W. Colman, J. Hirsh, V.J. Marder, A.W. Clowes, J.N. George (Eds.).
38. Gopalakrishnan R, Hedner U, Ghosh S, Nayak RC, Allen TC, Pendurthi UR, et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010, 8:301-310.
39. Lopez-Vilchez I, Hedner U, Altisent C, Diaz-Ricart M, Escolar G, Galan AM Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. Am J Pathol 2011, 178:2938-2948.
40. Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, Peyvandi F, et al. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thromb Res 2013, 132:256-262.
41. Morfini M, Batorova A, Mariani G, Auerswald G, Bernardi F, Di Minno G, et al. Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect. Thromb Haemost 2014, 112:424-425.
42. Di Minno MN, Dolce A, Mariani G Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost 2013, 109:1051-1059.
43. Nicolaisen EM Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998, 9(Suppl. 1):S119-S123.
44. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005, 3:2619-2626.
45. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006, 4:766-773.
46. Batorova A, Mariani G, Kavakli K, De Saez AR, Caliskan U, Karimi M, et al. Inhibitors to factor VII in congenital factor VII deficiency. Haemophilia 2014, 20:e188-e191.
47. Neufeld EJ, Negrier C, Arkhammar P, Benchikh el Fegoun S, Simonsen MD, Rosholm A, et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Reviews 2015, 29(Suppl. 1):S34-S41.
48. Mariani G, Dolce A, Batorova A, Auerswald G, Schved JF, Siragusa S, et al. Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER. Br J Haematol 2011, 152:340-346.
49. Monroe DM, Hoffman M, Oliver JA, Roberts HR Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997, 99:542-547.
50. Weeterings C, de Groot PG, Adelmeijer J, Lisman T The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 2008, 112:3227-3233.
51. Poon M-C Factor VIIa. Platelets 2013, 1257-1273. Academic Press, New York. A.D. Michelson (Ed.).